北京大学人民医院风湿免疫科是我国风湿病事业奠基人贺联印教授在上世纪80年代建立的中国最早的风湿病专业之一。在栗占国教授带领下，科室不断发展壮大，2012年成为北京市风湿病重点实验室和北京市国际科技合作基地，2013年成为国家临床重点专科，国家教育部重点学科，2015年获批教育部创新团队，2016年成为国内唯一的亚太风湿病中心。在中国最佳医院、医院科技和临床影响力两个排行榜中均在本学科排名第二。

　　本学科利用患者血清、关节液标本为核心的临床资源数据库及多学科技术平台，形成3个主要研究方向：阐明类风湿关节炎（RA）发生发展的危险因素和遗传背景；探讨我国常见风湿病的发病机制；通过循证研究提出适合我国国情的风湿病防治策略。近年来以提高风湿病的临床医疗水平为出发点，以疑难重症风湿病诊疗及防治为主线，依托跨学科研究及学术交流，在风湿病的流行病学、遗传背景、病理生理、免疫炎症机制及诊断、防治等方面开展深入研究。在RA的流行病学、SLE治疗和风湿病遗传背景等部分领域达到国际先进水平，成为全面发展的国内风湿病领域主要领军单位之一，业已在国际风湿病学领域占有一席之地。

　　学科一直保持稳定并稳健发展，目前拥有医生及研究人员64名，技术人员3人。其中正高职7名（博导6名），副高职14名。拥有国家自然科学基金委杰出青年1名、教育部新世纪人才1人，北京市科技新星4人。是一支充满无限活力的研究队伍。

　　目前本学科病房拥有52张病床，临床检验室、B超室、骨密度室等临床部门。建立起按病种分类的长期随访门诊，包括类风湿关节炎、系统性红斑狼疮、干燥综合征、痛风、IgG4相关疾病、强直性脊柱炎等。通过普通门诊－病房－随访门诊的一体化流程，为风湿病患者提供全方位的诊治和随访服务，显著改善患者病情和生活质量。全年门诊量超过10万例次。此外作为开放实验室，建有免疫室、分子和遗传室、细胞室等，拥有数千万的较为先进的实验仪器，基本满足各种实验条件，实现“临床－实验室－临床”的转化医学研究。曾获得中华医学科技二等奖、华夏医学科技二等奖等多个奖项。

　　近年来，该中心负责了多项国家级课题，牵头了多项全国多中心研究，推出抗a胞衬蛋白、膜DNA抗体等多种诊断标志物；提出了国际上首个ERA分类标准，在国内外发表，并推动了该标准的临床应用；在国际上首次应用IL-2靶向生物药治疗SLE获得成功，并用于临床，并证明了IL2的分子机制，是多年来国际上在SLE治疗领域的突破，成果发表于《Nature Medicine》（IF30.357）；牵头研究的“三联缓解方案”(PRINT)将RA缓解率大幅度提高，已用于临床治疗，大量患者受益。为国际公认的最实用的高缓解率方案，成为欧洲风湿病联盟(EULAR)的RA治疗指南引用的唯一循证（RCT）研究。

　　

　　机构负责人：栗占国

　　联系人：李玉慧

　　邮箱：liyuhui84@163.com

　　电话：010-88324178

　　地址：北京市西直门南大街11号北京大学人民医院（科研楼）4层

　　网站：http://www.bdfs.org.cn

　　

　　Peking University Center of Clinical Immunology

　　The Rheumatology and Immunology Division of Peking University People’s Hospital is one of the first Chinese immunology Division that established in the 1980s by the founder of Chinese Rheumatologist, Professor Lian-yin He. In the 1990s, under the leadership of Prof. Zhan-guo Li, our division has been developing substantially. It has been crowned as the key laboratory of Rheumatology disease of the Beijing 2012, as the key discipline of China and Ministry of education in 2013, as the innovation team of the Ministry of education in 2015, as the Asia Pacific League of Associations (APLAR) center of Rheumatology in 2016. The division has been ranked as No 2 consecutively in several ranking systems in China, including Fudan version of the best clinical discipline, the prestigious research as well as the clinical influence in China.

　　Based on multidisciplinary technological platform and the database of clinical cohorts, our division has been focusing on three main directions of scientific research:

　　To investigate the pathogenesis of common autoimmune diseases, especially Rheumatoid Arthritis(RA);

　　2. To identify the risk factors and genetic background in developing and progression of RA;

　　3．To develop diagnosis and treatment strategies of RA and SLE in China using evidence-based research.

　　In recent years, aiming to improve capacity of clinical service, focusing on the diagnosis and treatment of complicated and severe autoimmune diseases, developing prevention and treatment strategy of autoimmune diseases, we have performed cutting edge academic research in autoimmune diseases epidemiology, genetic background, rheumatoid pathophysiology, immune-inflammatory pathogenesis and evidence-based treatment of autoimmune diseases with international reputation. Rheumatology and immunology Division of Peking University People’s Hospital is recognized as one of the top ranked rheumatoid program in the world.

　　Our division has been keeping fast pace of stable and steady development; we have 64 Rheumatologists and physician-scientists, 3 technicians. Among the Rheumatologists and physician-scientists, there are 7 full professors and 14 associated professors. 1 has been awarded as outstanding youth of national natural science foundation of China (NSFC), 1 has been ranked as the new century talents pioneers of Ministry of Education, 4 have been awarded as Beijing nova of municipal science and technology. Our rheumatoid program has been recognized as a young, passionate and dynamic one.

　　At present, our division includes 1 ward (52 beds), 1 clinical laboratory and a ultrasonic team and a Bone density team. We have established long-term follow-up clinics according to various clinical cohorts, including Rheumatoid arthritis, systemic lupus erythematosus, sjogren syndrome, ankylosing spondylitis, Gout, IgG4 related disease etc. Through the integration of Rheumatology wards and follow up clinics, we provide a full range of diagnosis, treatment and follow-up services for patients with autoimmune diseases, which somehow significantly improved the patient's health condition and quality of life. Our division has more than 100 thousand outpatients visits annually. In addition, as an open laboratory, we provide research platforms on immunology, molecular genetics, histopathology, cellular biology etc. In our research laboratory, we have advanced experimental instruments that could meet the need of most translational research. We have won a great number of awards such as the second prize for Chinese medical science and technology, the second prize in the Chinese medical science.

　　We conducted several national multi-center survey of RA and SLE in China, we studied several diagnositic biomarkers such as a Fodrin antibody, mDNA. We raised the first diagnostic criteria of ealy-RA in the world. And we revealed low-dose IL-2 therapy is effective and safe in SLE by reinstating the balance of the immune system, and this achievement has been published on (Nature Medicine, IF 30.357).We  conducted the multicenter study about RA elucidated that prolonged intensive DMARD therapy(PRINT) in RA can bring high remission. Many patients with RA obtained benefit from the PRINT stategy. And this result was the only RCT study cited by ELUAR recommendations for the management of RA.

　　Chief of Rheumatology Division, Peking University People’s Hospital: Prof. Zhan-guo Li

　　Contacts: Dr. Yu-hui Li

　　Email address: liyuhui84@163.com

　　Telephone: 010-88324178

　　Address: 4th Floor, Experimental Lab Center, Peking University People’s Hospital

　　11 Xizhimen south St., Xicheng District, Beijing 100044

　　P.R.China 

　　Official Website: http://www.bdfs.org.cn